Post-dural Puncture Headache - Needles and Biomarkers in CSF

Post-dural Puncture Headache Clinical Trial

Official title:

Quincke vs. Sprotte and Post-dural Puncture Headache - a Randomised Controlled Trial

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02384031
• Other study ID #: 2011/1083/REK nord
• Status: Completed
• Phase: N/A
• Start date: February 2012
• Est. completion date: March 31, 2019

Study information

• Verified date: April 2019
• Source: Nordlandssykehuset HF
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Post-dural puncture headache (PDPH) is the most common complication following lumbar puncture (LP). The frequency varies widely depending on a number of factors, among which patient characteristics, case ascertainment, gauge and type of needle used are of significant importance. In 2001, Strupp et al. showed that over 12 % of 115 patients who were subjected to diagnostic lumbar puncture with a 22 gg (0.7 mm) atraumatic needle suffered post-dural puncture headache, while over 24 % of 115 who were given a lumbar puncture with a 22 gg traumatic needle suffered a headache. This finding provided the basis for an American recommendation to use a 22 gg atraumatic needle for diagnostic lumbar puncture. A later study with 58 patients has shown an even greater difference (36 % versus 3 % post-dural puncture headache) when an atraumatic needle is used. Despite these findings, European Neurologist continue to hold on to the cutting needle. Here the investigators propose a prospective randomized study design with double masking; neither patient nor evaluator of PDPH aware of the needle design used, and with an active ascertainment of the occurrence of PDPH in accordance with updated headache classification guidelines. The investigators also intend to investigate whether specific neuroinflammatory substances and metabolites (different outcome variables) in the cerebrospinal fluid (CSF) will affect the explanatory variable.

Description:

Subjects are patients scheduled for a diagnostic LP as part of their routine clinical management at the department of Neurology, Nordland Hospital in Bodø, Norway. Selection is based on the inclusion and exclusion criteria listed beneath, independent of the primary clinical indication for the procedure.

Informed consenting patients will be randomised in two groups based on needle type. The traumatic group using Spinocan® (Quincke) 22Gx3.5" needle and atraumatic group using Pencan® (Sprotte) 22Gx3.5" needle. The randomisation process will be via an internet web-based application, provided by Norwegian university of science and Technology (http://www.ntnu.edu/dmf/akf/randomisering).

Subjects will undergo standard lumbar puncture, all in lateral recumbent position, the needle inserted, preferentially in level L3-4, perpendicular or parallel to the dural fibers, and CSF will be collected in accordance with the study protocol. Information about the LP, eventual complications, CSF volumes tapped and standard CSF-findings are noted.

Follow-up will be performed by investigators that are masked to the randomization. Patients will be interviewed over the telephone, alternatively in person if hospitalised, the first 1 and 7th day after the LP.Subjects that do develop PDPH will be treated in-line with established and standardized protocols at the department of Neurology, Nordland Hospital Trust, Bodø. Given that PDPH has a natural history of spontaneous resolution within 1-12 days, patients suffering from PDPH will be treated conservatively for the duration of the first 7 days after PDPH diagnosis. Conservative therapy, based on symptoms severity and patients' responsiveness, consist of the following: bed rest, caffeine, analgesics (paracetamol, NSAIDS), antiemetics and i.v. hydration. If the headache is severe and disabling and non-respondent after 7 days of conservative therapy, epidural blood patch will be administered. If a patient diagnosed with PDPH has a change in the pain character, or develops additional neurological manifestations, an urgent brain CT scan or MRI is indicated to exclude rarer potentially life-threatening intracranial complications.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 172
• Est. completion date: March 31, 2019
• Est. primary completion date: March 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

1. Patients at Department of Neurology, Nordland Hospital Trust in Bodø, scheduled for diagnostic LP

Exclusion Criteria:

1. Dementia

2. Non-compliance or coma

3. Local skin infections over proposed puncture site

4. Suspicion of raised intracranial pressure due to neurological or radiological findings

5. Bleeding diathesis (thrombocytopenia <50 x 109/L) or ongoing anticoagulant therapy

6. Major spinal column deformities

7. Procedural complications whereby needle type or size change is a requisite

8. Recent LP (< 7 days)

Related Conditions & MeSH terms

• Headache
• Post-Dural Puncture Headache

Intervention

Device:
• Traumatic needle
Lumbar puncture is performed with a traumatic needle
• Atraumatic needle
Lumbar puncture is performed with an atraumatic needle

Locations

Country	Name	City	State
Norway	Departement of Neurology, NLSH HF	Bodø

Sponsors (3)

Lead Sponsor	Collaborator
Nordlandssykehuset HF	Imperial College London, Norwegian University of Science and Technology

Country where clinical trial is conducted

Norway, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Post-dural puncture headache (PDPH)		At day 7 post LP
Secondary	Levels of neuropeptides in CSF		During lumbar puncture
Secondary	Levels of metabolites in CSF		During lumbar puncture
Secondary	Levels of inflammatory mediators in CSF		During lumbar puncture